A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532) – EUROPEAN UROLOGY ONCOLOGY

Tombal, BF; Gomez-Veiga, F; Gomez-Ferrer, A; López-Campos, F; Ost, P; Roumeguere, TA; Herrera-Imbroda, B; D’Hondt, LA; Quivrin, M; Gontero, P; Villà, S; Khaled, H; Fournier, B; Musoro, J; Krzystyniak, J; Pretzenbacher, Y; Loriot, Y – 2024 – 10.1016/j.euo.2024.01.009